Sarah M. Tolaney, MD, MPH, discusses the range of treatment options for early-stage HER2+ breast cancer, including subcutaneous options and investigational therapies.
May 6th 2022
Sarah M. Tolaney, MD, MPH, provides an overview of how goals of care and prognosis differ between patients with early-stage HER2+ breast cancer and advanced or metastatic HER2+ breast cancer.
Sarah M. Tolaney, MD, MPH, reviews the treatment options for patients with early-stage HER2+ breast cancer in the frontline setting.
May 11th 2022
An expert oncologist explains the combination subcutaneous injection therapy of pertuzumab, trastuzumab, and hyaluronidase-zzxf for patients with early-stage HER2+ breast cancer.
Sarah M. Tolaney, MD, MPH, describes her usage of pertuzumab, trastuzumab, and hyaluronidase-zzxf subcutaneous injections in her clinical practice during the COVID-19 pandemic for patients with HER2+ breast cancer.
May 18th 2022
A key opinion leader explains how she discusses treatment options and trial data with patients with early stage HER2+ breast cancer.
Dr Sarah M. Tolaney discusses whether maintenance therapy has a role in HER2+ breast cancer treatment.
Sarah M. Tolaney, MD, MPH, highlights recent and investigative treatments for HER2+ breast cancer that excite her and provides some clinical pearls for community oncologists.